Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Current portion of long-term debt $4,474,131 $2,651,592 Current portion of capital lease obligation - 41,641 Accounts payable 3,708,060 2,466,052 Accrued expenses 6,060,141 6,182,417 Deferred rent 124,462 124,463 Deferred revenue 1,857,136 1,857,136 --------- --------- Total current liabilities 16,223,930 13,323,301 DEFERRED RENT 48,421 79,793 DEFERRED REVENUE 3,404,674 3,868,965 LONG-TERM DEBT, net 18,053,545 16,522,665 ---------- ---------- Total liabilities 37,730,570 33,794,724 ---------- ---------- COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 23,390,862 and 23,340,498 shares issued and outstanding at December 31, 2008 (unaudited) and September 30, 2008, respectively 23,391 23,340 Warrants to purchase 127,248 and 116,183 shares of common stock for $12.05 per share, as of December 31, 2008, (unaudited) and September 30, 2008, respectively 1,229,767 1,140,114 Additional paid-in capital 147,600,186 145,818,439 Accumulated other comprehensive (loss) income (1,515) (2,604) Accumulated deficit (130,067,341) (111,791,944)
'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues  ("BioLife" or the ... Annual Meeting of Stockholders on May 4, 2015 (the ... the Annual Meeting represents a change of more than ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 On ... law H.R. 83, the Omnibus and Continuing Resolution ... time, made hydrocephalus a condition eligible to receive ... (CDMRP) administered by the Department of Defense (DoD). ... its allies on Capitol Hill, is celebrating this ...
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Coulter, Inc. (NYSE: BEC ), a leading ... and innovate complex biomedical testing, announced today it will ... at 5:00 p.m. ET to discuss the company,s third ... call, there will be a webcast presentation of accompanying ...
... 13 Osteotech, Inc. (Nasdaq: OSTE ), ... for regenerative healing, announced today that it has received ... Commission granted early termination of the Hart-Scott-Rodino waiting period ... of the merger remains subject to antitrust clearance in ...
... 13, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:Beckman Coulter to host Conference Call and Webcast Presentation for Third Quarter 2010 Earnings Results on October 27, 2010 2Osteotech Announces Early Termination of HSR Waiting Period 2Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 2Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 3Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 4Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 5Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 6Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 7Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 8
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... water pathogens may get a lot easier and cheaper thanks ... his team. , Syed Hashsham, an associate professor in ... for Microbial Ecology, is developing a portable, hand-held device capable ... water and food. , "This device will give ...
... failure and other health conditions, blood draws and diagnostic tests ... chemical or physiologic changes silently cause damage that is not ... future a tiny device, one the size of a nickel ... monitor and detect abnormalities, and could then relay data to ...
... the thymus, where the immune system's T cells develop, if ... thousands of proteins as "self." The research confirms an ... the immune system, and not only at the sites where ... of type 1 diabetes, or the joints in rheumatoid arthritis. ...
Cached Biology News:Professors to develop hand-held pathogen testing device 2Cardiologist's 'living chip' changes science of disease monitoring 2Cardiologist's 'living chip' changes science of disease monitoring 3Cardiologist's 'living chip' changes science of disease monitoring 4Proteins anchor memories in our brain 2Proteins anchor memories in our brain 3
Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Antigen: Synthetic peptide corresponding to...
Polyclonal Antibody to TRIB1/ SKIP1/ Tribbles 1...
TNF-Related Apoptosis Inducing Ligand-Receptor-1...
PMA (YPMA-1)...
Biology Products: